Liftya is a bracing solution that preserves the range of motion, improving the rehabilitation and quality of life of patients with shoulder disorders.
Shoulder instability occurs when the head of the upper arm bone is forced out of the shoulder socket, resulting in a loss of functionality and pain. This condition is experienced by patients with either musculoskeletal or neurological disorders, and up to 80% of the patients with stroke complications suffer from shoulder instability due to arm impairment. Consequently, these patients require several months of joint immobilisation, costly dependent care, and experience a delayed return to work.
Typical solutions for shoulder instability usually involve braces and slings that hold the shoulder in the appropriate position to prevent further complications. A significant and well-documented limitation of existing braces is that they limit the range of motion and do not facilitate motor recovery.
Liftya is a patented ‘spherical hinge mechanism’ that replicates the behaviour of the shoulder joint by maintaining in its position. Its design preserves the range of motion, alleviates pressure on the shoulder joint, and increases independence by allowing the patient to perform daily activities. Liftya improves patient comfort and reduces pain while also reducing the costs for the healthcare system.
The CEO, Alberto Verteramo, who holds a Ph.D. in bioengineering, has more than 18 years of experience in the healthtech industry, including global R&D, international marketing, sales management, and medical education. Leveraging his extensive know-how from major companies, he has decided to apply his experience to a startup in order to bring better innovations and positively impact patients’ lives.
Liftya technology is protected by international patents. The company is filing for CE regulatory documentation and plans to obtain approval by Q1 2024. The team aims to capture anatomical fast data and deliver 3D quick production, in collaboration with a R&D consulting partner. Advanced kinematics analysis will be done in collaboration with the University of Politecnico of Torino and Aalborg University, both renowned bioengineering departments, starting in November 2023. Clinical trials at both ortho and neuro rehabilitation centres will commence in Q3 2024
‘…Liftya has been designed with two goals in mind: get patients to use their arm again, and support physiotherapists to accelerate rehabilitation. It’s a powerful synergy trio…’ says Alberto Verteramo, CEO at Liftya
NLC is the leading European healthtech venture builder. NLC identifies top-notch early-stage healthcare inventions and brings them to market, acting as the connecting link between technology innovation and entrepreneurship in medtech, biotech and digital health. To optimize patient care and enhance its positive and sustainable impact, NLC collaborates with corporates such as Philips and healthcare and academic research institutions such as Oxford University and Mayo Clinic.
NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, 17. With its growing team of more than 80 professionals and over 110 portfolio ventures built across 11 European countries, NLC is currently expanding its impact-driven operations to the US and the Gulf region.
FOR MORE INFORMATION
Liftya | https://liftya.health/home/
Alberto Verteramo | CEO
Via Eutimene 58 – 00124, Rome, Italy.